- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04684563
huCART19-IL18 in CD19+ Cancers
Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase I dose finding study to determine the maximum tolerated dose (MTD) and assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of huCART19-IL18 cells in patients with CD19+ cancers. Up to 7 total dose levels will be evaluated using the Bayesian Optimal Interval (BOIN) design with accelerated titration in order to determine the maximum tolerated dose (MTD) of huCART19-IL18 cells within each of the following disease-specific cohorts:
- Cohort A: Non-Hodgkin Lymphoma (NHL)
- Cohort B: Chronic Lymphocytic Leukemia (CLL)
- Cohort C: Acute Lymphoblastic Leukemia (ALL)
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Abramson Cancer Center Clinical Trials Service
- Phone Number: 855-216-0098
- Email: PennCancerTrials@careboxhealth.com
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Abramson Cancer Center Clinical Trials Service
- Phone Number: 855-216-0098
- Email: PennCancerTrials@careboxhealth.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Signed informed consent form
Documentation of CD19 expression on malignant cells a. Cohort A (NHL): Within 6 months of physician-investigator confirmation of eligibility as long as there has been no intervening CD19 directed therapy since expression confirmed. Results outside of this window may be used, if there is no accessible tumor site and the subject did not receive intervening CD19 directed therapy since CD19 expression was confirmed.
b. Cohorts B (CLL) and C (ALL): At time of most recent relapse
Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:
- Have no active GVHD and require no immunosuppression
- Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility
Adequate organ function defined as:
- Creatinine ≤ 1.6 mg/dl
- ALT/AST ≤ 3x upper limit of normal range
- Direct bilirubin ≤ 2.0 mg/dl, unless the subject has Gilbert's syndrome (≤3.0 mg/dl)
- Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air
- Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA
- Evidence of active disease within 12 weeks of physician-investigator confirmation of eligibility. .
- Male or female age ≥ 18 years.
- ECOG Performance Status that is either 0 or 1.
- Subjects of reproductive potential must agree to use acceptable birth control methods.
Disease-specific criteria:
a. Cohort A (NHL): i. Patients with any of the following diagnoses: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS), germinal center or activated B-cell types; Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (i.e. "Double or Triple Hit"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.
1. Patients must have either relapsed after, or be ineligible for, prior CAR T cell therapy, and meet one of the following criteria:
- Relapsed/refractory disease after at least 2 prior lines of appropriate therapy and are ineligible for autologous stem cell transplant; OR
- Relapsed/refractory disease after autologous SCT; OR
Relapsed/refractory disease after allogeneic SCT. ii. Follicular lymphoma
- Patients must have either relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND
- Received at least 2 prior lines of appropriate therapy (not including single agent monoclonal antibody therapy) and progressed within 2 years after second or higher line of therapy.
iii. Mantle cell lymphoma
- Patients must have either failed standard of care CAR T cell therapy (e.g. Tecartus™, etc) or other investigational CAR T cell product, OR be ineligible for standard of care Tecartus™; and
Patients must also meet one of the following criteria:
- Relapsed/refractory disease after at least 2 prior lines of appropriate therapy, including a BTK inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy; OR
- Relapsed/refractory disease after prior autologous SCT; OR
- Relapsed/refractory disease after prior allogeneic SCT. iv. Large cell transformation of CLL (Richter's Transformation)
1. Patients must be primary refractory or received at least 1 prior line of treatment.
b. Cohort B (CLL): i. Patients with relapsed/refractory disease after at least 2 prior lines of appropriate therapy; AND ii. Patients must have previously received, or be intolerant to an approved BTK inhibitor and venetoclax, unless a BTK inhibitor or venetoclax is contraindicated.
c. Cohort C (ALL): i. Patients with b-cell acute lymphoblastic leukemia. Note: Chronic myeloid leukemia (CML) lymphoid blast crisis is considered a sub-type of relapsed B-ALL, thus will be encompassed in our definition of B-ALL throughout; AND ii. Patients with 2nd or greater relapse or refractory disease as defined by one of the following criteria:
- Recurrent disease in the blood or bone marrow identified morphologically, by IHC or flow; OR
- Isolated CNS disease. Note: Patients with prior/current history of CNS3 disease will only be eligible for treatment if the CNS disease is responsive to therapy; OR
- Recurrent extramedullary disease at other (non-CNS) sites if disease response can be assessed radiographically. Note: Patients with recurrent extramedullary disease do not need to have detectable blood or bone marrow involvement; OR
- Any relapse after allogeneic SCT; OR
Patients with refractory disease as defined by one of the following:
- Failure to achieve remission (<5% bone marrow blasts or ongoing extramedullary or CNS disease) after 2 cycles of induction chemotherapy; OR
- Patients that achieve remission but remain MRD+ after ≥2 cycles of induction chemotherapy.
Exclusion Criteria:
- Active hepatitis B, active hepatitis C, or other active, uncontrolled infection.
- Class III/IV cardiovascular disability according to the New York Heart Association Classification.
- Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.
- Active acute or chronic GVHD requiring systemic therapy.
- Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.
- RETIRED WITH PROTOCOL AMENDMENT V7
- Receipt of prior huCART19 therapy.
CNS disease as defined by disease-cohort as follows:
- Cohorts A + B: Active CNS disease. Note: Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs/symptoms of CNS involvement.
- Cohort C: CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
- Pregnant or nursing (lactating) women.
- Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to their cancer or previous cancer treatment.
- Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NHL Dose Level 1a (DL1a)
3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: NHL Dose Level -1 (DL-1)
7x10^5 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 1a.
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: NHL Dose Level 1b (DL1b)
3x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: NHL Dose Level 2 (DL2)
7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: NHL Dose Level 3 (DL3)
3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: NHL Dose Level 4 (DL4)
7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: NHL Dose Level 5 (DL5)
3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: CLL Dose Level 1b (DL1b)
3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: CLL Dose Level 2 (DL2)
7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: CLL Dose Level 3 (DL3)
3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: CLL Dose Level 4 (DL4)
7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: CLL Dose Level 5 (DL5)
3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: ALL Dose Level 1b (DL1b)
3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: ALL Dose Level 2 (DL2)
7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: ALL Dose Level 3 (DL3)
3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: ALL Dose Level 4 (DL4)
7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
Experimental: ALL Dose Level 5 (DL5)
3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
|
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: 12 months
|
12 months
|
|
Overall Survival (OS)
Time Frame: 12 months
|
12 months
|
|
Percentage of manufacturing products that meet release criteria.
Time Frame: 3 months
|
3 months
|
|
Duration of Response (DOR)
Time Frame: 12 months
|
12 months
|
|
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells
Time Frame: 12 months
|
Polychromatic flow cytometry-based assessment of leukemia and B cells, extent and duration of leukemic response
|
12 months
|
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells
Time Frame: 12 months
|
Presence or absence of malignant B cells by Next-Generation Immunoglobulin heavy chain Sequencing (NGIS)
|
12 months
|
Occurrence of dose-limiting toxicities (DLTs).
Time Frame: 3 months
|
3 months
|
|
Determination of Maximum Tolerated Dose (MTD)
Time Frame: 3 months
|
3 months
|
|
Overall Response Rate (ORR).
Time Frame: 3 months
|
Cohort A (NHL) and Cohort B (CLL)
|
3 months
|
Overall Remission Rate (ORR).
Time Frame: 1 months
|
Cohort C (ALL)
|
1 months
|
Best Overall Response (BOR)
Time Frame: 3 months
|
Cohort A (NHL) and Cohort B (CLL)
|
3 months
|
Best Overall Response (BOR)
Time Frame: 6 months
|
6 months
|
|
Event Free Survival (EFS)
Time Frame: 12 months
|
Cohort C (ALL)
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jakub Svoboda, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Leukemia, Lymphoid
- Leukemia, B-Cell
- Chronic Disease
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
Other Study ID Numbers
- UPCC15420; IRB# 844955
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
Therapeutic Advances in Childhood Leukemia ConsortiumEnzon Pharmaceuticals, Inc.TerminatedLymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T CellUnited States, Australia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia | Adult Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on huCART19-IL18
-
University of PennsylvaniaKite, A Gilead CompanyRecruiting
-
University of PennsylvaniaCompletedAcute Lymphocytic Leukemia | Diffuse Large Cell LymphomaUnited States
-
University of PennsylvaniaChildren's Hospital of PhiladelphiaActive, not recruitingAcute Lymphoid LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
University of PennsylvaniaNovartisActive, not recruitingMultiple MyelomaUnited States
-
University of PennsylvaniaActive, not recruitingRefractory Acute Lymphoblastic Leukemia | Chemotherapy Resistant Acute Lymphoblastic LeukemiaUnited States
-
Stephan Grupp MD PhDUniversity of PennsylvaniaRecruitingB-cell Acute Lymphoblastic Leukemia | B Lineage Lymphoblastic LymphomaUnited States
-
Stephan Grupp MD PhDChildren's Hospital of PhiladelphiaRecruitingB Cell Acute Lymphoblastic Leukemia (B-ALL) | B Lineage Lymphoblastic LymphomaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Pennsylvania Clinical Cell and Vaccine Production Facility...Not yet recruitingKidney Failure | End Stage Renal Failure on Dialysis | Kidney TransplantUnited States